35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management

Clinical Definition, Rome IV Criteria & Brain-Gut Axis Pathophysiology

Irritable bowel syndrome (IBS) is the most common disorder of gut-brain interaction (DGBI; formerly functional gastrointestinal disorder) encountered in clinical practice, affecting approximately 5% to 10% of the global adult population, with a 1.5- to 2-fold female predominance. Historically classified as a diagnosis of exclusion, IBS is now recognized as a distinct, positive neurogastroenterological entity characterized by dysregulation of bidirectional communication along the brain-gut-microbiome axis.

The Rome IV Diagnostic Criteria

According to the Rome IV consensus guidelines, a definitive diagnosis of IBS requires:

Recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with TWO or more of the following criteria:

1. Related to defecation (either improvement or worsening of pain);
2. Associated with a change in stool frequency (increased or decreased number of bowel movements);
3. Associated with a change in stool form (appearance) (transition to hard/lumpy or loose/watery stools).

Temporal Requirement: Diagnostic criteria must be fulfilled for the past 3 months, with initial symptom onset occurring at least 6 months prior to diagnosis.

Critical Distinction from Rome III: Rome IV eliminated the term "abdominal discomfort" (which was culturally vague) and mandated that pain must be the cardinal symptom. Additionally, while Rome III required pain to be "relieved by defecation," Rome IV recognized that defecation may either relieve or exacerbate abdominal pain in affected patients.

Pathophysiological Mechanisms

IBS is a multifactorial biopsychosocial disorder involving several interconnected pathways:

1. Visceral Hypersensitivity (Hyperalgesia & Allodynia): Patients demonstrate a lowered sensory threshold for mechanical bowel wall distension. Normal physiological volumes of intraluminal gas or stool elicit severe pain signals via primary sensory afferent neurons transmitting to the dorsal horn of the spinal cord and the anterior cingulate cortex.
2. Altered Gastrointestinal Motility: Disordered enteric smooth muscle contractility causes accelerated colonic transit (manifesting as diarrhea and fecal urgency) or delayed transit (manifesting as severe constipation and straining).
3. Low-Grade Mucosal Inflammation & Epithelial Permeability: Subgroups of patients, especially those with post-infectious IBS (PI-IBS) following an episode of acute bacterial gastroenteritis (Campylobacter, Salmonella, Shigella), exhibit persistent mucosal mast cell hyperplasia, elevated mucosal tryptase and histamine, and impaired tight junction integrity, allowing luminal antigenic penetration.
4. Intestinal Microbiome Dysbiosis: Reduced microbial alpha-diversity, decreased abundance of butyrate-producing commensals (Faecalibacterium prausnitzii, Bifidobacterium), and overgrowth of proinflammatory taxa.
5. Central Neuroprocessing & Autonomic Dysregulation: Chronic psychosocial stress, anxiety, depression, and adverse childhood events alter hypothalamic-pituitary-adrenal (HPA) axis signaling, driving hypercortisolemia and sympathetic overdrive, which blunts descending central pain inhibition.

---

Subtyping IBS via the Bristol Stool Form Scale (BSFS)

Accurate phenotypic subtyping is essential because therapeutic algorithms differ fundamentally across subtypes. Subtyping must be evaluated exclusively on days when the patient has abnormal bowel movements (defecations associated with pain or altered consistency):

The Bristol Stool Form Scale (BSFS)

• Type 1: Separate hard lumps, like nuts (hard to pass; indicates severely delayed transit).
• Type 2: Sausage-shaped, but lumpy (indicates slow transit and constipation).
• Type 3: Like a sausage with cracks on its surface (normal).
• Type 4: Like a sausage or snake, smooth and soft (normal; optimal stool consistency).
• Type 5: Soft blobs with clear-cut edges (passed easily; indicates rapid transit).
• Type 6: Fluffy pieces with ragged edges, a mushy stool (indicates diarrhea).
• Type 7: Watery, no solid pieces, entirely liquid (indicates severe diarrhea).

Phenotypic Subtyping Classification

---

Diagnostic Strategy: Positive Diagnostic Approach vs. Exhaustive Testing

Historical medical practice relied on performing batteries of unrevealing, expensive, and invasive diagnostic tests to exclude all possible organic pathologies before offering an IBS diagnosis. Modern clinical guidelines from the American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) strongly deprecate this practice, recommending a positive diagnostic approach.

The Positive Diagnostic Approach

In a patient presenting with typical Rome IV symptoms in the absence of alarm red flags, a positive diagnosis of IBS can be established with >95% diagnostic certainty during the initial outpatient visit. Exhaustive testing increases patient health anxiety, delays effective therapy, and confers zero diagnostic yield.

Routine Recommended Initial Laboratory Evaluation

For all patients presenting with suspected IBS, standard evaluation is limited to:

1. Complete Blood Count (CBC): Screens for occult gastrointestinal blood loss, iron deficiency anemia, and leukocytosis.
2. Inflammatory Biomarkers: Serum C-Reactive Protein (CRP) OR Fecal Calprotectin.
   • Clinical Pearl: A fecal calprotectin level <50 mcg/g has a negative predictive value >98% for excluding active inflammatory bowel disease (Crohn's or ulcerative colitis), avoiding unnecessary colonoscopy.
3. Celiac Disease Serologic Screening:
   • Serum tissue Transglutaminase IgA (anti-tTG IgA) coupled with Total Serum IgA (to detect selective IgA deficiency).
   • Recommended routinely in all patients with IBS-D or IBS-M, as celiac disease presents with identical symptoms in 2% to 4% of suspected IBS cases.
4. Targeted Stool Testing:
   • Routine stool ova and parasites (O&P) or enteric bacterial cultures are NOT recommended in unselected patients, but should be reserved for individuals with persistent diarrhea who report untreated surface water exposure, wilderness travel, or foreign travel to endemic regions (specifically testing for Giardia duodenalis antigen).

Alarm Red Flags Mandating Endoscopic Colonoscopy

If ANY of the following alarm features are identified, a positive IBS diagnosis cannot be presumed, and prompt structural evaluation with colonoscopy (and cross-sectional imaging when indicated) is mandatory:

                     ALARM RED FLAGS REQUIRING COLONOSCOPY

     • Age ≥45 to 50 years at initial symptom onset
     • Frank rectal bleeding (hematochezia) or melena (not attributable to hemorrhoids)
     • Unintentional, documented weight loss (>5-10% of body weight)
     • Nocturnal diarrhea that awakens the patient from sleep
     • Unexplained microcytic or iron deficiency anemia
     • Documented fever or signs of systemic illness
     • Palpable abdominal mass or lymphadenopathy
     • Family history of colorectal cancer (CRC), inflammatory bowel disease (IBD),
       or celiac disease in a first-degree relative
     • Rapidly progressive or uncharacteristically severe symptom worsening

---

Dietary & Lifestyle Interventions

Non-pharmacologic lifestyle and dietary modifications represent the essential foundation of IBS therapy for all subtypes:

1. The Low-FODMAP Diet

• FODMAP Definition: Fermentable Oligosaccharides (fructans [wheat, onions, garlic], galacto-oligosaccharides/GOS [legumes, beans]), Disaccharides (lactose [dairy]), Monosaccharides (excess fructose [honey, apples, mangoes]), and Polyols (sorbitol, mannitol, xylitol [stone fruits, artificial sweeteners]).
• Pathophysiology: FODMAPs are short-chain carbohydrates that are poorly absorbed in the human small intestine. Because they are osmotically active, they pull water into the small bowel lumen (accelerating transit and triggering watery diarrhea). Upon entering the colon, they undergo rapid enzymatic fermentation by colonic bacteria, releasing hydrogen, carbon dioxide, and methane gas. In patients with visceral hypersensitivity, this gas causes mechanical distension, leading to severe abdominal bloating, flatulence, and crampy pain.
• Evidence-Based 3-Phase Implementation:
  1. Phase 1: Elimination (Strict Restriction): Strict avoidance of high-FODMAP foods for 4 to 6 weeks. Patients who experience clinical benefit progress to Phase 2; non-responders should discontinue the diet.
  2. Phase 2: Reintroduction (Systematic Rechallenge): Over 6 to 8 weeks, individual FODMAP food categories are systematically reintroduced one at a time over 3-day test windows to identify specific personal dietary triggers while continuing a low-FODMAP baseline.
  3. Phase 3: Personalization (Long-Term Maintenance): Tailoring a personalized, long-term sustainable diet that excludes only the identified culprit FODMAP groups.

  • [!IMPORTANT]

  • Safety Warning: Strict, perpetual Phase 1 elimination is strongly discouraged because it reduces prebiotic intake, significantly decreases beneficial bifidobacteria in the colonic microbiome, and predisposes to micronutrient deficiencies.

2. Dietary Fiber Optimization

• Soluble Fiber (Psyllium / Ispaghula Husk): Soluble, viscous, fermentable fiber absorbs water to form a soft, gelatinous stool matrix, normalizing transit time in both IBS-C and IBS-M. Recommended as first-line therapy starting at 5 to 10 g daily and titrating to 20 to 30 g/day with copious fluid intake.
• Insoluble Fiber (Wheat Bran): Exam Pearl: Insoluble wheat bran increases colonic gas production, flatulence, and bloating, and frequently worsens overall IBS abdominal pain. It is not recommended for IBS.

3. Regular Exercise & Sleep Hygiene

• Engaging in 20 to 60 minutes of moderate-to-vigorous physical activity 3 to 5 days weekly accelerates colonic gas clearance, improves intestinal transit, and reduces IBS symptom severity scores.

---

Subtype-Specific Pharmacotherapy

When dietary and lifestyle modifications provide incomplete relief, subtype-specific pharmacotherapy is initiated in a stepwise manner.

Comprehensive Pharmacotherapy Hierarchy for IBS Subtypes

---

Targeted Management of Chronic Visceral Pain & Gut-Brain Neuromodulation

Abdominal pain in IBS is driven by central and peripheral visceral hypersensitivity. When lifestyle measures and secretagogues or antimotility agents fail to control pain, central neuromodulators must be utilized:

1. Antispasmodics (Smooth Muscle Relaxants)

• Dicyclomine (10 to 20 mg PO three to four times daily PRN) and Hyoscyamine (0.125 to 0.25 mg PO/SL three to four times daily PRN):
  • Antagonize muscarinic M3 receptors on colonic smooth muscle, attenuating postprandial hypercontractility and painful colonic spasms.
  • Best taken 30 to 45 minutes before meals in patients with predictable postprandial cramping.
  • Adverse Effects: Systemic anticholinergic effects: dry mouth, blurred vision, urinary retention, tachycardia, and drowsiness. Avoid in elderly patients (Beers Criteria).
• Enteric-Coated Peppermint Oil (0.2 to 0.4 mL PO three times daily before meals):
  • Contains L-menthol, which acts as a natural calcium channel blocker on intestinal smooth muscle cells, inducing smooth muscle relaxation and reducing visceral spasms with high safety.

2. Central Gut-Brain Neuromodulators

• Tricyclic Antidepressants (TCAs) — The Preferred Analgesic for IBS-D:
  • Amitriptyline, Nortriptyline, or Desipramine (10 to 25 mg orally at bedtime, titrating slowly to 25 to 50 mg nightly).
  • Mechanism: Doses are sub-therapeutic for depression; TCAs alter central processing of visceral sensory afferents, downregulate spinal cord dorsal horn nociception, and induce moderate anticholinergic delaying of intestinal transit.
  • Clinical Match: Ideal for IBS-D and patients with severe, chronic nocturnal or constant visceral pain. Should generally be avoided in IBS-C due to worsening constipation.
• Selective Serotonin Reuptake Inhibitors (SSRIs) — The Preferred Option for IBS-C:
  • Citalopram (10-20 mg daily), Sertraline (25-50 mg daily), or Escitalopram (10 mg daily).
  • Mechanism: Stimulate 5-HT4 receptors to accelerate whole-gut transit, while downregulating anxiety and visceral hypervigilance.
  • Clinical Match: Preferred for IBS-C and patients with prominent comorbid generalized anxiety disorder, panic disorder, or somatic symptom distress.

3. Gut-Directed Behavioral Interventions

• The American College of Gastroenterology guidelines strongly recommend Gut-Directed Cognitive Behavioral Therapy (CBT) and Gut-Directed Hypnotherapy (such as the Manchester Protocol).
• These specialized psychological modalities train patients in cognitive restructuring, visceral relaxation, and downregulating autonomic arousal, demonstrating durable clinical benefits for abdominal pain that persist for years without pharmacologic side effects.